Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Atorvastatin Treatment Report
What is Atorvastatin?

Atorvastatin is an antilipemic agent used for the treatment of dyslipidemias or primary prevention of cardiovascular disease (atherosclerotic).

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Other 12 1
General health 11 1
Cholesterol high 7 2
high tryglicerides 1 0
Slow my ALS progress 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
3 100%

Dosages

  daily 5 mg daily 10 mg daily 20 mg daily 40 mg daily 80 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1 7 Number of Patients: 7 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Atorvastatin (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
6 38% Doctor's advice: 38%
Personal research
3 19% Personal research: 19%
Side effects too severe
3 19% Side effects too severe: 19%
Other
3 19% Other: 19%
Expense
1 6% Expense: 6%
Not indicated
1 6% Not indicated: 6%

See all 15 patients who’ve stopped taking Atorvastatin

Currently Taking Atorvastatin

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
1
7

Stopped Taking Atorvastatin

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
4
0
11

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
3 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
3 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 33%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 23, 2009.